FOLH1 and neoplasm: Another radiopharmaceutical with great therapeutic potential, 177Lu-PSMA-617, specifically identifies tumor cells with high expression of PSMA and releases β-particles to destroy tumor cells, was recently evaluated in the just concluded VISION trial (117).